Graft Versus Host Disease Market Insights-01

DelveInsight’s Graft Versus Host Disease (GvHD) report provides an overview of the disease and market size of GvHD for the seven major markets i.e., the United States, EU5 (France, Germany, Italy, Spain, the UK) and Japan.

Some Key highlights from the Graft Versus Host Disease Market Report

  • According to a report by Elgaz S. et al. (2019), “aGvHD affects 30–50% of recipients, and 14% of all patients have serious aGvHD grades 3–4.” Chronic GvHD affects 30–70% of patients who undergo allo-SCT.
  • According to Orphanet, approximately 35 percent to 50 percent of hematopoietic stem cell transplant (HSCT) recipients will experience acute Graft versus Host disease (GvHD). In addition, approximately half of patients with acute GvHD can develop chronic GvHD at some stage.
  • According to the report “Introduction of Chronic Graft-versus-Host Disease (GvHD)” by Riches (n.d.), about 50% of all patients who receive an allogeneic transplant (transplant using donor cells) experience chronic GvHD.
  • Key Pipeline therapies in the GvHD market include Ruxolitinib (Incyte Corporation/Novartis), Itacitinib (Incyte Corporation), Uvadex (Methoxsalen), Leukotac (Elsalys Biotech), KD025 (Kadmon Corporation), Glassia (Kamada), ApoGraft (Cellect Biotechnology), SNDX-6352 (Syndax Pharmaceuticals) and others.
  • Key companies involved in the GvHD market are Incyte Corporation, Novartis, Methoxsalen, Elsalys Biotech, Kadmon Corporation, Kamada, Cellect Biotechnology, Syndax Pharmaceuticals, among others.

For more information, request sample page @ Graft Versus Host Disease Market Insights

The Graft Versus Host Disease market report provides current treatment practices, emerging drugs Graft Versus Host Disease market share of the individual therapies, current and forecasted Graft Versus

Host Disease market size during the study period of 2017-30 in the 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France), and Japan).

Graft Versus Host Disease: Overview

Graft Versus Host Disease (GvHD) is a condition marked by inflammation in various organs. GvHD is typically associated with stem cell and bone marrow transplants. The donor’s immune system’s white blood cells, which reside inside the donated tissue (the graft), identify the recipient (the host) as a foreign body (non-self). The white blood cells in the transplanted tissue then invade the cells in the recipient’s body, resulting in GvHD.

Read more about GvHD Treatment Options and Trends

There are two forms of GvHD:

  • Acute Graft Versus Host Disease (aGvHD)
  • Chronic Graft Versus Host Disease (cGvHD)

Graft Versus Host Disease Epidemiology Segmentation

  • Hematopoietic Stem Cell Transplantations Diagnosed Incident Cases
  • Allogeneic HSCT Diagnosed Incident Cases
  • aGvHD Diagnosed Incident Cases of first Allogeneic HSCT Diagnosed Incident Cases
  • cGvHD Diagnosed Incident Cases of first Allogeneic HSCT Diagnosed Incident Cases

Get more details about epidemiology @ Graft Versus Host Disease Epidemiology

Graft Versus Host Disease Treatment Landscape

The major therapies used in treatment and prevention of GvHD are classified into:

  • Corticosteroids (methylprednisolone and prednisolone)
  • Calcineurin inhibitors (Cyclosporine)
  • ATG therapies (Grafalon)
  • IL2Rα (CD25) inhibitors (Simulect)
  • TNFα inhibitors (Remicade and Enbrel)
  • Co-stimulatory blockers (Orencia and Nulojix)
  • Calcineurin inhibitors(Cyclosporine)
  • mTOR inhibitors(Rapamune and Certican)
  • SOT therapies (CellCept/Myfortic and Prograf)
  • Antineoplastic therapies (Velcade, Gleevec, Methotrexate, Nipent and Cyclophosphamide)
  • Stem Cell Treatments (remestemcel-L)
  • Other biologics (Lemtrada and Rituxan/MabThera)

Graft Versus Host Disease Market

Key companies including Incyte Corporation, Novartis, Methoxsalen, Elsalys Biotech, Kadmon Corporation, Kamada, Cellect Biotechnology, Syndax Pharmaceuticals, among others are expected to enter the GvHD market with new therapies.

The introduction of Ruxolitinib (Incyte Corporation/Novartis), Itacitinib (Incyte Corporation), Uvadex (Methoxsalen), Leukotac (Elsalys Biotech), KD025 (Kadmon Corporation), Glassia (Kamada), ApoGraft (Cellect Biotechnology) and SNDX-6352 (Syndax Pharmaceuticals) are expected to give the GvHD market a significant boost in the forecast period 2017-30 in the 7MM.

Furthermore, extensive R&D in the domain, as well as increasing GvHD prevalence, are driving the GvHD market forward.

Graft Versus Host Disease Pipeline Therapies and Key Companies

  • Ruxolitinib: Incyte Corporation/Novartis
  • Itacitinib: Incyte Corporation
  • Uvadex: Methoxsalen
  • Leukotac: Elsalys Biotech
  • KD025: Kadmon Corporation
  • Glassia: Kamada
  • ApoGraft: Cellect Biotechnology
  • SNDX-6352: Syndax Pharmaceuticals

Visit for more about emerging therapies and key companies @ GvHD Emerging Drugs and Key Companies

Graft Versus Host Disease Market Drivers

  • Increase in research activities
  • Increasing disease prevalence
  • Surge in a number of clinical studies

Graft Versus Host Disease Market Barriers

  • Treatment costs
  • Need for novel therapeutics
  • Need for targeted treatment regimen

Scope for the Report

Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain and France) and Japan)

Study Period: 2017-30

GvHD Key Companies: Incyte Corporation, Novartis, Methoxsalen, Elsalys Biotech, Kadmon Corporation, Kamada, Cellect Biotechnology, Syndax Pharmaceuticals, among others.

GvHD Pipeline Therapies: Ruxolitinib (Incyte Corporation/Novartis), Itacitinib (Incyte Corporation), Uvadex (Methoxsalen), Leukotac (Elsalys Biotech), KD025 (Kadmon Corporation), Glassia (Kamada), ApoGraft (Cellect Biotechnology), SNDX-6352 (Syndax Pharmaceuticals) and others.

GvHD Market Segmentation: By Geography, By GvHD Therapies

Analysis: Comparative and conjoint analysis of GvHD emerging therapies

Cases Studies

KOL’s Views

Analyst’s Views

For more details visit @ Graft Versus Host Disease Market Insights

Table of Contents

1. Report Introduction
2. GvHD Market Overview at a Glance
3. Disease Background and Overview: Graft versus Host Disease (GvHD)
4. GvHD Epidemiology and Patient Population
5. Graft Versus Host Disease Epidemiology
6. United States Epidemiology
7. EU5 Epidemiology
8. Japan Epidemiology
9. GvHD Treatment Algorithm
10. GvHD Unmet Needs
11. GvHD Marketed Drugs
12. GvHD Emerging Therapies
13. GvHD Therapeutics
14. GvHD Prophylaxis
15. Other Promising Candidates
16. Total Market Size of GvHD in 7MM
17. 7MM Market Size by Therapies
18. United States-GvHD Market
19. EU5-GvHD Market
20. Japan-GvHD Market
21. GvHD Market Drivers
22. GvHD Market Barriers
23. Appendix
24. Report Methodology
25. Consulting Services
26. Disclaimer
27. About DelveInsight

Know more about report offering @ Graft Versus Host Disease Market

Related Reports

Antibody-Mediated Graft Rejection Market

DelveInsight’s “Antibody-Mediated Graft Rejection – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Antibody-Mediated Graft Rejection , historical and forecasted epidemiology as well as the Antibody-Mediated Graft Rejection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Steroid Refactory Acute Graft-Versus-Host Disease Market

DelveInsight’s “Steroid Refactory Acute Graft-Versus-Host Disease (GVHD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Steroid Refactory Acute Graft-Versus-Host Disease (GVHD), historical and forecasted epidemiology as well as the Steroid Refactory Acute Graft-Versus-Host Disease (GVHD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Generalized Myasthenia Gravis Market

DelveInsight’s “Generalized Myasthenia Gravis (gMG) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Generalized Myasthenia Gravis (gMG), historical and forecasted epidemiology as well as the Generalized Myasthenia Gravis (gMG) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Granulomatosis With Polyangiitis Market

Get comprehensive historical and forecast analysis of Granulomatosis With Polyangiitis Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Genentech, Biogen Idec, GlaxoSmithKline, Bristol-Myers Squibb, among others.

Graves Ophthalmopathy Market

DelveInsight’s “Graves Ophthalmopathy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Graves Ophthalmopathy, historical and forecasted epidemiology as well as the Graves Ophthalmopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Myasthenia Gravis Market

DelveInsight’s “Myasthenia Gravis – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Myasthenia Gravis, historical and forecasted epidemiology as well as the Myasthenia Gravis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

High Grade Glioma Market

Get comprehensive historical and forecast analysis of High Grade Glioma Market, Epidemiological and Therapeutics market domain with a special focus on key companies such as Merck, Orbus Therapeutics,  Bayer, MedImmune, DNAtrix, among others. 

Low-Grade Upper Tract Urothelial Cancer Market

DelveInsight’s “Low-Grade Upper Tract Urothelial Cancer (LG UTUC) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Low-Grade Upper Tract Urothelial Cancer (LG UTUC) , historical and forecasted epidemiology as well as the Low-Grade Upper Tract Urothelial Cancer (LG UTUC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Multidrug-resistant Gram-negative (MDRGN) Infection Market

DelveInsight’s “Multidrug-resistant Gram-negative (MDRGN) Infection – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Multidrug-resistant Gram-negative (MDRGN) Infection, historical and forecasted epidemiology as well as the Multidrug-resistant Gram-negative (MDRGN) Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Graves Orbitopathy Market

DelveInsight’s “Graves Orbitopathy – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Graves Orbitopathy , historical and forecasted epidemiology as well as the Graves Orbitopathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Get in touch with our Business executive @ Rare Disease Market Insights to know more

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.